Lipid nanoparticles (LNPs) are effective non-viral carriers, which are widely used as delivery vehicles for gene-based drugs such as messenger RNA (mRNA). To mitigate safety risks and ensure product efficacy, it is important to comprehensively characterize the lipids used for LNPs and their related impurities, as well as the mRNA integrity, purity and its critical quality attributes (CQAs).
Webinar Date/Time: Wed, May 3, 2023 11:00 AM EDT
Lipid-based nanoparticles (LNPs) are effective non-viral vectors for delivering messenger RNA products (mRNA), most notably used for vaccine production against the recent SARS-CoV-2 pandemic. In this executive summary, you will discover a robust and high-throughput kit-based analysis of nucleic acids extracted from different mRNA-LNP samples.
As more gene therapy applications make inroads into research and clinical practice, the development and safe manufacturing of the therapeutic products involved have demanded more from associated analytical technologies. One of the most widely used gene-therapy vectors is AAV, and key technologies for the characterization of AAVs include CE and LC-MS.
Tuesday, December, 7, 2021 at 11 AM CET | 5 am EST | 10 am GMT Ever wondered how mRNA vaccines are produced and analyzed? Attend this webinar to discover how mRNA vaccines are produced and tested by CE.